Professional Documents
Culture Documents
Transmitted
Disease
Surveillance
2015:
February 2017
Acknowledgments
Publication of this report would not have been possible without the contributions of
participating state and local health departments, sexually transmitted disease clinics, public
health laboratories, and regional laboratories
Alesia Harvey, Viani Ramirez, Tremeka Sanders, and Elizabeth Torrone, Surveillance and Data
Management Branch of the Division of STD Prevention, National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.
Copyright Information
All material contained in this report is in the public domain and may be used and reprinted
without special permission; however, citation as to source is appreciated.
Suggested Citation
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2015:
Gonococcal Isolate Surveillance Project (GISP) Supplement and Profiles. Atlanta: U.S.
Department of Health and Human Services; 2017.
Web Site
Although gonorrhea is an ancient disease that has affected humans for centuries and effective
therapy has been available since the early twentieth century, this sexually transmitted disease
(STD) remains prevalent: gonorrhea is the second most commonly reported notifiable disease in
the United States and 395,216 cases were reported in 2015.1 As with other STDs, the reporting of
gonorrhea is incomplete and the Centers for Disease Control and Prevention (CDC) estimates
that approximately 820,000 cases of gonorrhea occur yearly in the United States.2 Infections
due to Neisseria gonorrhoeae are a major cause of pelvic inflammatory disease (PID) in the
United States. PID can lead to serious reproductive outcomes in women, such as tubal infertility,
ectopic pregnancy, and chronic pelvic pain.
The cornerstone of public health gonorrhea control is detection and treatment of gonorrhea, so
as to prevent sequelae and limit disease transmission. For decades, gonorrhea has been easily
treated with a single dose of a single antimicrobial agent. However, N. gonorrhoeae has
progressively developed resistance to each antimicrobial used for treatment of gonorrhea. In the
last decade, development of fluoroquinolone resistance resulted in the availability of only a
single class of antimicrobials that met CDCs efficacy standards the cephalosporins. Recently,
declining susceptibility to cefixime resulted in a change to the CDC treatment guidelines, so that
dual therapy with ceftriaxone and azithromycin is the only CDC-recommended treatment
regimen for uncomplicated gonorrhea.3 Continued surveillance of N. gonorrhoeae antimicrobial
susceptibility is critical.
The Gonococcal Isolate Surveillance Project (GISP) was established in 1986 to monitor trends in
antimicrobial susceptibilities of N. gonorrhoeae strains in the United States to establish an
evidence-based rationale for selection of gonococcal therapies. GISP is a sentinel surveillance
system and collaboration between participating STD clinics and their state or local public health
authorities, GISP regional laboratories, and CDC.
N. gonorrhoeae isolates are collected monthly from up to the first 25 men with gonococcal
urethritis attending participating STD clinics. Clinical and demographic data are abstracted
from medical records. Isolates are shipped from participating clinics to the GISP regional
laboratories for agar dilution antimicrobial susceptibility testing. Isolates are tested to
determine minimum inhibitory concentrations (MICs) of penicillin, tetracycline, ceftriaxone,
cefixime, ciprofloxacin, and azithromycin. Cefixime susceptibility testing was discontinued in
2007 and re-started in 2009. Cefpodoxime susceptibility testing was conducted during 2009
2012.
Findings from GISP have directly contributed to CDCs STD Treatment Guidelines in 1993,
1998, 2002, 2006, 2010, and 2015 and updates in 2000, 2004, 2007, and 2012. Data from GISP
have also been presented in multiple scientific papers and conference presentations. Additional
information on GISP and links to recent publications can be found on the GISP website:
https://www.cdc.gov/std/gisp/default.htm.
STD clinics affiliated with 24 state or city health departments contributed 5,147 gonococcal
isolates to GISP in 2015. Of these sites, 11 current sites have participated continuously since
1987: Albuquerque, New Mexico; Atlanta, Georgia; Birmingham, Alabama; Honolulu, Hawaii;
New Orleans, Louisiana; Philadelphia, Pennsylvania; Phoenix, Arizona; Portland, Oregon; San
Diego, California; San Francisco, California; and Seattle, Washington. The other current sites
are: Boston, Massachusetts (19871992, 20142015); Buffalo, New York (20142015); Chicago,
Illinois (19962015); Cleveland, Ohio (19912015); Columbus, Ohio (20122015); Dallas, Texas
(19992015); Greensboro, North Carolina (20022015); Indianapolis, Indiana (20132015);
Kansas City, Missouri (19922001, 20072015); Los Angeles, California (20032015); Las
Vegas, Nevada (20022015); Minneapolis, Minnesota (19922015); New York, New York
(20062015); Orange County, California (19912015); Pontiac, Michigan (20122015); and
Tripler Army Medical Center, Hawaii (20012015).
Susceptibility to cefixime
Susceptibility testing for cefixime began in 1992, was discontinued in GISP in 2007, and was re-
started in 2009. The distribution of cefixime MICs each year from 20112015 is displayed in
Figure 1 and Table 1. Each year, over 90% of isolates exhibited cefixime MICs 0.03 g/ml.
The percentage of isolates with elevated cefixime MICs (0.25 g/ml) declined from 1.4% in
2011 to 0.5% in 2015. Site-specific data are presented in the Site Profiles section of this report
(Figure H).
Susceptibility to ceftriaxone
Susceptibility testing for ceftriaxone began in 1987. The distribution of ceftriaxone MICs each
year from 20112015 is displayed in Figure 2 and Table 2. Each year, approximately 90% of
isolates exhibited ceftriaxone MICs 0.015 g/ml. The percentage of GISP isolates that
exhibited elevated ceftriaxone MICs, defined as 0.125 g/ml, decreased from 0.4% in 2011 to
0.3% in 2015. Site-specific data are presented in the Site Profiles section of this report (Figure
G).
Additional data on susceptibility to ceftriaxone can be found in Sexually Transmitted Disease
Surveillance 2015.1
Susceptibility to azithromycin
Susceptibility testing for azithromycin began in 1992. The distribution of azithromycin MICs
each year from 20112015 is displayed in Table 3 and Figure 3. Most isolates had azithromycin
MICs of 0.1250.25 g/ml. The proportion of GISP isolates with azithromycin MICs of 2.0
g/ml increased from 0.3% in 2011 to 2.6% in 2015. Site-specific data are presented in the Site
Profiles section of this report (Figure J).
Additional data on susceptibility to azithromycin can be found in Sexually Transmitted Disease
Surveillance 2015.1
Susceptibility to ciprofloxacin
Susceptibility testing for ciprofloxacin began in 1990. The proportion of GISP isolates with
ciprofloxacin resistance (MIC 1 g/ml) peaked in 2007 at 14.8%. Following a decline in 2008 and
2009, the proportion increased to 22.3% by 2015. The prevalence of resistance increased sharply
among isolates from gay, bisexual and other men who have sex with men (MSM) during the
2000s, and peaked at 38.9% in 2006 (Figure 4). In 2015, 32.1% of isolates from MSM exhibited
ciprofloxacin resistance. The prevalence of ciprofloxacin resistance increased during 2000
2007 among isolates from men who report sex exclusively with women (MSW), decreased
during 2008 and 2009, and increased during 20102015. In 2015, 16.4% of isolates from MSW
exhibited ciprofloxacin resistance. Site-specific data on intermediate resistance and resistance to
ciprofloxacin are presented in the Site Profiles section of this report (Figure I).
Site Profiles
The Site Profiles consist of figures depicting the demographic and clinical data of the men who
submitted specimens for GISP and the antimicrobial susceptibility results of the N. gonorrhoeae
isolates submitted. Each figure is labeled with the participating site and the number of isolates
on which the sites data are based. The maximum number of isolates submitted by each site
annually is 300. The number of isolates submitted is lower for some sites located in areas with
low gonorrhea morbidity.
Figure B: Cases are reported using Office of Management and Budget (OMB) compliant race
and ethnicity categories. The Other category includes participants who selected more than one
race category and participants with unknown race.
Figure C: Men who self-identified as gay or bisexual or reported recent male sex partners were
categorized as men who have sex with men.
The majority of these criteria are also recommended by the Clinical and Laboratory Standards
Institute (CLSI).4
* Resistance to cefixime and ceftriaxone, and resistance and susceptibility to azithromycin are
not defined by CLSI.
Additional resources
Additional information on GISP, as well as useful resources and links, can be found on the CDC
Division of STD Prevention (DSTDP) Antimicrobial Resistant Gonorrhea website:
https://www.cdc.gov/std/Gonorrhea/arg/default.htm
Other United States surveillance data on N. gonorrhoeae and other STDs and additional data
from GISP may be found on the CDC DSTDP Surveillance and Statistics website:
https://www.cdc.gov/std/stats/
Data on antimicrobial resistance in N. gonorrhoeae and other bacterial pathogens may be found
in CDCs report, Antibiotic Resistance Threats in the United States, 2013:
https://www.cdc.gov/drugresistance/threat-report-2013/
References
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 0.5 1.0
MICs (g/ml)
Figure 2. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs)
Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance
Project (GISP), 2011-2015
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 0.5
MICs (g/ml)
Figure 3. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs)
Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance
Project (GISP), 2011-2015
40
2011
2012
2013
2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
Figure 4. Percentage of Neisseria gonorrhoeae Isolates that are Ciprofloxacin-
Resistant by Reported Sex of Sex Partner, Gonococcal Isolate
Surveillance Project (GISP), 1995-2015
45
MSM* MSW*
40
35
30
Percentage
25
20
15
10
0
1995 96 97 98 99 2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
*MSM=men who have sex with men; MSW=men who have sex with women only.
Table 1. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs)
Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance
Project (GISP), 20112015
0.030 0.060 0.125 0.250 0.500 1.000 2.000 4.000 8.000 16.00 Total
Year n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Albuquerque, New Mexico (N=115)
60
50
40
Percentage
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Albuquerque, New Mexico
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Albuquerque, New Mexico (N=115)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
100.0%
Ceftriaxone 250 mg
Albuquerque, New Mexico (N=115)
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
99.1% 0.9%
Azi/Ery Doxy/Tet
Albuquerque, New Mexico (N=115)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
1.7%
83.5% 2.6%
1.7%
0.9%
3.5%
3.5%
2.6%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Albuquerque, New Mexico
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Albuquerque, New Mexico
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
40
2011
2012
2013
2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Atlanta, Georgia (N=299)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Atlanta, Georgia (N=299)
100
90
80
70
60
Percentage
50
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Atlanta, Georgia
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Atlanta, Georgia (N=299)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
0.7%
2.0%
97.0%
0.3%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.0%
2.0%
Azi/Ery None/Other
Atlanta, Georgia (N=299)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
3.3%
3.7%
4.3%
67.2% 0.7%
8.4%
8.0%
4.3%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Atlanta, Georgia
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Atlanta, Georgia
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
40
2011
2012
2013
2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Birmingham, Alabama (N=175)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Birmingham, Alabama (N=175)
100
90
80
70
60
Percentage
50
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Birmingham, Alabama
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
10
6
Percentage
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Birmingham, Alabama (N=175)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
89.7%
5.7%
4.6%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
81.6%
9.8%
8.6%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
5.7%
75.4% 3.4%
1.1%
0.6%
5.1%
8.0%
0.6%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Birmingham, Alabama
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Birmingham, Alabama
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Boston, Massachusetts (N=38)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Boston, Massachusetts (N=38)
60
50
40
Percentage
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Boston, Massachusetts
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
80
70
60
50
Percentage
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
2.6%
97.4%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
94.7%
5.3%
Azi/Ery Doxy/Tet
Boston, Massachusetts (N=38)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
42.1%
7.9%
2.6%
2.6%
10.5%
2.6%
18.4%
13.2%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Buffalo, New York (N=140)
90
80
70
60
Percentage
50
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Buffalo, New York
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
20
18
16
14
12
Percentage
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
0.7%
99.3%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.6% 1.4%
Azi/Ery Doxy/Tet
Buffalo, New York (N=140)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
8.6%
2.1%
5.0%
0.7%
5.7%
1.4%
0.7%
75.7%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
40
2011
2012
2013
2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Chicago, Illinois (N=150)
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Chicago, Illinois
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
50
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Chicago, Illinois (N=150)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
99.3%
0.7%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.6%
1.4%
Azi/Ery None/Other
Chicago, Illinois (N=150)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
69.3% 1.3%
4.0%
0.7%
8.7%
6.7%
9.3%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Chicago, Illinois
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Chicago, Illinois
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
20
15
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
40
2011
2012
2013
2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Cleveland, Ohio (N=123)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Cleveland, Ohio (N=123)
90
80
70
60
Percentage
50
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Cleveland, Ohio
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
30
20
Percentage
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Cleveland, Ohio (N=123)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
72.4%
26.8%
0.8%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
85.4%
12.2%
2.4%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
76.4%
1.6%
2.4%
3.3%
0.8%
5.7%
7.3%
2.4%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Cleveland, Ohio
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Cleveland, Ohio
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
18
16
14
12
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
60
2011
2012
2013
50 2014
2015
40
Percentage
30
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Columbus, Ohio (N=300)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Columbus, Ohio (N=300)
80
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Columbus, Ohio
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
30
20
Percentage
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
96.0%
4.0%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
92.3%
4.0%
3.7%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
74.3%
5.3%
0.3%
3.3%
1.3%
6.7%
5.3%
3.3%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
16
12
Percentage
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
60
2011
2012
2013
50 2014
2015
40
Percentage
30
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Dallas, Texas (N=283)
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Dallas, Texas
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Dallas, Texas (N=283)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.9%
1.1%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
99.6%
0.4%
Azi/Ery Doxy/Tet
Dallas, Texas (N=283)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
64.7%
4.9%
3.2%
3.5%
0.7%
5.3%
14.5%
3.2%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Dallas, Texas
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Dallas, Texas
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
18
16
14
12
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Greensboro, North Carolina (N=259)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Greensboro, North Carolina (N=259)
100
90
80
70
60
Percentage
50
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Greensboro, North Carolina
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
30
20
Percentage
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
100.0%
Ceftriaxone 250 mg
Greensboro, North Carolina (N=259)
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
100.0%
Azi/Ery
Greensboro, North Carolina (N=259)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
0.8%
14.7%
61.8%
0.8%
1.2%
6.6%
10.8%
3.5%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Greensboro, North Carolina
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Greensboro, North Carolina
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Honolulu, Hawaii (N=123)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Honolulu, Hawaii (N=123)
30
20
Percentage
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Honolulu, Hawaii
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
70
60
50
Percentage
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Honolulu, Hawaii (N=123)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
99.2%
0.8%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.4%
1.6%
Azi/Ery None/Other
Honolulu, Hawaii (N=123)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
8.1%
48.0%
6.5%
2.4%
0.8%
4.1%
4.1%
26.0%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Honolulu, Hawaii
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Honolulu, Hawaii
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
50
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
60
2011
2012
2013
50 2014
2015
40
Percentage
30
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Indianapolis, Indiana (N=298)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Indianapolis, Indiana (N=298)
80
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Indianapolis, Indiana
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
25
20
15
Percentage
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
0.3%
6.0%
92.3%
1.3%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
92.3%
7.0%
0.7%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
75.2%
3.0%
0.3%
4.4%
0.7%
7.0%
7.4%
2.0%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
16
12
Percentage
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
40
2011
2012
2013
2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Kansas City, Missouri (N=270)
90
80
70
60
Percentage
50
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Kansas City, Missouri
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
10
6
Percentage
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
95.9%
0.7%
1.1%
2.2%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
97.0%
2.6%
0.4%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
4.4%
7.8%
5.2%
0.7%
1.5%
70.4%
7.0%
3.0%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Kansas City, Missouri
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Kansas City, Missouri
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Las Vegas, Nevada (N=300)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Las Vegas, Nevada (N=300)
50
40
30
Percentage
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Las Vegas, Nevada
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
50
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
100.0%
Ceftriaxone 250 mg
Las Vegas, Nevada (N=300)
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
100.0%
Azi/Ery
Las Vegas, Nevada (N=300)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
4.7%
55.7%
8.3%
3.7%
0.3%
8.7%
16.7%
2.0%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Las Vegas, Nevada
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Las Vegas, Nevada
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Los Angeles, California (N=81)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Los Angeles, California (N=81)
40
30
Percentage
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Los Angeles, California
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
90
80
70
60
Percentage
50
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
6.2%
1.2%
90.1%
2.5%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
93.8%
6.2%
Azi/Ery None/Other
Los Angeles, California (N=81)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
2.5%
12.3%
4.9%
1.2%
2.5%
55.6%
18.5%
2.5%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Los Angeles, California
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Los Angeles, California
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Minneapolis, Minnesota (N=105)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Minneapolis, Minnesota (N=105)
50
40
30
Percentage
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Minneapolis, Minnesota
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
70
60
50
Percentage
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Minneapolis, Minnesota (N=105)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.1%
1.9%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.1%
1.9%
Azi/Ery None/Other
Minneapolis, Minnesota (N=105)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
1.9%
6.7%
1.0%
55.2%
27.6%
1.0% 6.7%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Minneapolis, Minnesota
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Minneapolis, Minnesota
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
50
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
New Orleans, Louisiana (N=131)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
New Orleans, Louisiana (N=131)
90
80
70
60
Percentage
50
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
New Orleans, Louisiana
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
New Orleans, Louisiana (N=131)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
1.5%
25.4%
71.5% 1.5%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
74.6%
25.4%
Azi/Ery None/Other
New Orleans, Louisiana (N=131)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
62.6%
2.3%
6.1%
8.4%
3.8%
1.5%
15.3%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
New Orleans, Louisiana
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
New Orleans, Louisiana
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
New York City, New York (N=141)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
New York City, New York (N=141)
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
New York City, New York
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
60
50
40
Percentage
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
90.8%
1.4%
0.7%
7.1%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
92.2%
7.8%
Azi/Ery None/Other
New York City, New York (N=141)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
11.3%
53.9%
5.7%
9.9%
2.1%
7.1%
2.8% 7.1%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
New York City, New York
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
New York City, New York
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
40
2011
2012
2013
2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Orange County, California (N=183)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Orange County, California (N=183)
60
50
40
Percentage
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Orange County, California
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
80
70
60
50
Percentage
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Orange County, California (N=183)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
93.4%
0.5%
2.2%
3.8%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
94.0%
4.4%
1.6%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
47.0%
7.7%
6.0%
3.3%
4.9%
2.7%
12.0%
16.4%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Orange County, California
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Orange County, California
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
50
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Philadelphia, Pennsylvania (N=300)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Philadelphia, Pennsylvania (N=300)
80
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Philadelphia, Pennsylvania
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Philadelphia, Pennsylvania (N=300)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
93.0%
1.3%
5.7%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.7% 1.0%
0.3%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
17.0%
59.0%
2.0%
2.0%
2.3%
4.3%
3.0%
10.3%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Philadelphia, Pennsylvania
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Philadelphia, Pennsylvania
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Phoenix, Arizona (N=300)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Phoenix, Arizona (N=300)
50
40
30
Percentage
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Phoenix, Arizona
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
50
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Phoenix, Arizona (N=300)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
100.0%
Ceftriaxone 250 mg
Phoenix, Arizona (N=300)
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.7% 1.0%
0.3%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
6.0%
16.0%
43.0%
0.7%
1.0%
6.0%
1.7%
25.7%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Phoenix, Arizona
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Phoenix, Arizona
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
30
20
Percentage
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Pontiac, Michigan (N=198)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Pontiac, Michigan (N=198)
80
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Pontiac, Michigan
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
50
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
94.4%
3.6%
2.0%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
91.9%
3.0%
5.1%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
69.7% 4.5%
4.5%
0.5%
4.0%
10.6%
6.1%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
90
2011
2012
80
2013
2014
70 2015
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
16
12
Percentage
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
60
2011
2012
2013
50 2014
2015
40
Percentage
30
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Portland, Oregon (N=148)
70
60
50
Percentage
40
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Portland, Oregon
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
80
70
60
50
Percentage
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Portland, Oregon (N=148)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
97.3%
2.7%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
96.6%
3.4%
Azi/Ery Doxy/Tet
Portland, Oregon (N=148)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
2.0%
7.4%
43.2%
19.6%
4.1%
4.1%
5.4%
14.2%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Portland, Oregon
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
80
2011
2012
70 2013
2014
2015
60
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Portland, Oregon
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
60
50
40
Percentage
30
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
60
2011
2012
2013
50 2014
2015
40
Percentage
30
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
San Diego, California (N=189)
18
17
16
15
14
13
12
11
Percentage
10
9
8
7
6
5
4
3
2
1
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
San Diego, California (N=189)
50
40
30
Percentage
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
San Diego, California
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
90
80
70
60
Percentage
50
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
San Diego, California (N=189)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
98.4%
1.6%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
92.0%
8.0%
Azi/Ery None/Other
San Diego, California (N=189)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
36.5% 13.8%
5.3%
2.6%
4.8%
7.9%
9.5%
19.6%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
San Diego, California
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
San Diego, California
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
50
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
San Francisco, California (N=300)
30
20
Percentage
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
San Francisco, California (N=300)
40
30
Percentage
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
San Francisco, California
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
80
70
60
50
Percentage
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
San Francisco, California (N=300)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
99.3%
0.7%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
99.0% 1.0%
Azi/Ery Doxy/Tet
San Francisco, California (N=300)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
4.0%
9.0%
5.7%
42.0%
4.7%
11.3%
11.0%
12.3%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
San Francisco, California
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
San Francisco, California
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
50
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
60
2011
2012
2013
50 2014
2015
40
Percentage
30
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Seattle, Washington (N=187)
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Seattle, Washington (N=187)
60
50
40
Percentage
30
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Seattle, Washington
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
90
80
70
60
Percentage
50
40
30
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Seattle, Washington (N=187)
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
1.1%
69.5%
25.1%
4.3%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
30.5%
67.4%
2.1%
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
10.2%
50.3%
8.0%
2.7%
1.6%
7.0%
5.9%
14.4%
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Seattle, Washington
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
70
2011
2012
60 2013
2014
2015
50
Percentage
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Seattle, Washington
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
50
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
60
2011
2012
2013
50 2014
2015
40
Percentage
30
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)
.
Tripler Army Medical Center, Hawaii (N=11)
50
40
30
Percentage
20
10
0
<20 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Tripler Army Medical Center, Hawaii (N=11)
40
30
Percentage
20
10
0
White Black Hispanic Asian NHOPI AI/AN Multirace Other/Unk
NHOPI = Native Hawaiian or Other Pacific Islander; AI/AN = American Indian or Alaska Native; Unk = Unknown
Tripler Army Medical Center, Hawaii
Figure C. Percentage of GISP Participants Identifying as Men who Have Sex with Men, 2000-2015
40
30
Percentage
20
10
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Figure D. Primary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
88.9%
11.1%
Figure E. Secondary Antimicrobial Drug Used to Treat Gonorrhea Among GISP Participants, 2015
88.9%
11.1%
Azi/Ery None/Other
Tripler Army Medical Center, Hawaii (N=11)
Figure F. Percentage of GISP Isolates with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, 2015
90.9%
9.1%
Susceptible PenR/TetR/QRNG
Tripler Army Medical Center, Hawaii
Figure G. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.008 0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Tripler Army Medical Center, Hawaii
Figure H. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
100
2011
90 2012
2013
80 2014
2015
70
60
Percentage
50
40
30
20
10
0
<=0.015 0.03 0.06 0.125 0.25 >=0.5
MICs (g/ml)
Tripler Army Medical Center, Hawaii
Figure I. Percentage of GISP Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2015
40
30
Percentage
20
10
0
2000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
Figure J. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among GISP Isolates, 2011-2015
50
2011
2012
2013
40 2014
2015
30
Percentage
20
10
0
<=0.03 0.06 0.125 0.25 0.5 1.0 2.0 >=4.0
MICs (g/ml)